ReviewFrontiers in immunology2026
Depression and shortened survival in patients with cancer: a neuroimmune framework for bidirectional pathogenesis and therapeutic interception.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although depression is highly prevalent among patients with cancer and is consistently linked to shortened survival, its underlying biological mechanisms remain incompletely understood. While emerging evidence suggests that depression reshapes both systemic and tumor-localized immunity via β-adrenergic and glucocorticoid signaling, the broader integrative pathways remain to be fully defined. To address this gap, this review synthesizes evidence from clinical, epidemiological, and translational studies to present a unifying systems-level framework: depression influences cancer outcomes through the coordinated dysregulation of the autonomic nervous system (ANS), hypothalamic-pituitary-adrenal (HPA) axis, and neuroimmune network. Collectively, this triad fosters a pro-tumorigenic microenvironment. Unlike simpler linear models, this framework emphasizes the coupled, self-reinforcing interactions among these three systems. Specifically, sympathetic overdrive combined with vagal withdrawal amplifies the HPA output, peripheral inflammation sustains central dysregulation, and brain-derived neurotrophic factor (BDNF) dysfunction impairs neuroendocrine feedback. Herein, we critically evaluate the evidence supporting each node of this triad and highlight persistent controversies and evidence gaps, particularly regarding causal directionality and the translational divide between preclinical and human studies. Furthermore, we propose a targeted research agenda introducing three testable endophenotypes (HPA-dominant, inflammation-dominant, and cytotoxicity-dominant) designed to guide future biomarker-stratified immuno-oncology trials. We argue that while restoring autonomic-neuroendocrine-immune homeostasis represents a promising, testable strategy to improve survival, any related therapeutic recommendations remain strictly investigational until validated in large-scale randomized controlled trials with survival endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.